Ginkgo Bioworks CFO Steven Coen sells $2,302 in stock
At a glance
- $DNA today−2.82%last $8.26
- Vs industry peers−1.36 pts6-peer median −1.47% · behind
- Since Aug 25+14.2%from the first trade after the story
- 52-week range53.8% above low$5.37 – $18.22
- Cash runway~6 mo$84.5M cash ÷ $13.3M/mo burn · 10-Q
- In the headline$2,302Amount
Nothing reported about ginkgo bioworks across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: The headline hangs on one number ($2,302) — one data point is a snapshot, so the trailing trend is the context it needs.
- How the stock is trading: $DNA -2.82% in the latest session.
- Timing: It was published after the close, so the day's move was settled before the story existed. The next session is the first that could react.
Where the stock stands
Ginkgo Bioworks ($DNA) slipped 2.82% to $8.26 in the latest session. Over the past month it is down 18.0%. That leaves it 55% below its 52-week high of $18.22 and 54% above its low of $5.37. The year's high was 3.4 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 9, 2026), $DNA lost $41.0M over the quarter to Sep 30, 2026 on revenue of $27.7M (+37.5% QoQ). Operations used $119.3M of cash over the nine months to Sep 30, 2026 — about $13.3M a month — against $84.5M in cash on Sep 30, 2026. At that pace the cash covers about 6 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $551.8M against $84.5M of cash on Sep 30, 2026. Its most recent filings before this story: 10-Q on Aug 6, 2026, 8-K on Aug 5, 2026, 8-K on Jul 30, 2026. Figures are as filed with the SEC; the $DNA page has the full statements.
How much coverage it is getting
This story is more than a month old. Since then Wook has filed one newer story on Ginkgo Bioworks, published this week. It reads neutral.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $DNA page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. To run the numbers yourself, ask Wook AI above about $DNA: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on August 25, 2026. $DNA has moved +14.25% ($7.23 to $8.26). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
